Publication: 4413

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

Citation:: ESMO Open vol 9 (11)

Year:: 2024
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: collection

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 15

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, UG1CA232760; UG1CA233180, UG1CA233196, UG1CA233329, UG1CA233337, U10CA180820 (ECOG-ACRIN); U10CA180863 (Canadian Clinical Trials Group) and grant 704970 from the Canadian Cancer Society; U10CA180888 (SWOG)

Corr. Author:
Authors:: E. de Azambuja M. Piccart-Gebhart S. Fielding J. Townend D.W. Hillman M. Colleoni R. Roylance C.M. Kelly J. Lombard S. El-Abed A. Choudhury L. Korde M. Vicente S. Chumsri R. Rodeheffer S.L. Ellard A.C. Wolff J. Holtschmidt I. Lang M. Untch F. Boyle B. Xu G. Werutsky J. Tujakowski C.-S. Huang N.B. Baruch J. Bliss A. Ferro J. Gralow S.-B. Kim J.R. Kroep I. Krop S. Kuemmel R. McConnell L. Moscetti A.S. Knop F. van Duijnhoven H. Gomez D. Cameron S. Di Cosimo R.D. Gelber A. Moreno-Aspitia

Networks:: AL068, LAPS-CT018, LAPS-MA036, LAPS-MD017, LAPS-MN026, LAPS-NY016, SC019

Study: NCCTG-N063D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: